Prevalence of Vitamin D Deficiency in Slovak Women with Polycystic Ovary Syndrome and Its Relation to Metabolic and Reproductive Abnormalities

Overview

Journal Wien Klin Wochenschr

Publisher Springer

Specialty General Medicine

Date 2015 Mar 20

PMID 25787215

Citations 6

Authors

Jana Figurova

Ingrid Dravecka

Martin Javorsky

Jana Petrikova

Ivica Lazurova

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate prevalence of vitamin D deficiency and its relation to clinical, anthropometrical, and biochemical findings in polycystic ovary syndrome (PCOS) and controls.

Design: Case-control prospective observational study.

Settings: Department of Internal medicine, L.P. University hospital.

Patient(s): 99 PCOS women and 66 controls.

Main Outcome Measure(s): 25-hydroxyvitamin D level (25(OH)D), anthropometric, endocrine, and metabolic parameters in both groups.

Results: There was no significant difference in 25(OH)D levels between PCOS women and controls (24.79 ± 10.77 vs 25.07 ± 10.14 ng/ml, p = 0.868) and also in the prevalence of 25(OH)D deficiency in both groups (80 vs 70 %; p = 0.138). Vitamin D-deficient PCOS patients had significantly higher body mass index (BMI), fasting insulin, and homeostasis model assessment-insulin resistance (median [quartiles]: 2.24 [1.38; 3.51] vs 1.23 [0.79; 1.66]; p< 0.05, age-and BMI-adjusted p = 0.036) and borderline higher glycemia (4.7 ± 0.5 vs 4.5 ± 0.4 mmol/l; p = 0.05; p_adj = 0.95) compared with vitamin D-deficient controls. PCOS women with metabolic syndrome (MS) had lower serum 25(OH)D compared with those without MS (20.6 ± 8.3 vs 25.9 ± 11.3 ng/ml, p = 0.049). 25(OH)D correlated positively with high-density lipoprotein cholesterol in all subjects (r = 0.159, p = 0.043) and negatively with luteinizing hormone/follicle-stimulating hormone ratio (r = - 0.211, p = 0.037).

Conclusion: Insulin resistance and other metabolic abnormalities in PCOS women seem to be related to PCOS rather than to vitamin D deficiency.

Citing Articles

Association between serum 25-hydroxy vitamin D level and menstrual cycle length and regularity: A cross-sectional observational study.

Singh V, Tamar N, Lone Z, Das E, Sahu R, Majumdar S Int J Reprod Biomed. 2022; 19(11):979-986.

PMID: 34977455 PMC: 8717082. DOI: 10.18502/ijrm.v19i11.9913.

A systematic review and meta-analysis of the association between vitamin D and ovarian reserve.

Karimi E, Arab A, Rafiee M, Amani R Sci Rep. 2021; 11(1):16005.

PMID: 34362981 PMC: 8346573. DOI: 10.1038/s41598-021-95481-x.

Low Vitamin D Level in Saudi Women With Polycystic Ovary Syndrome.

Bindayel I Front Nutr. 2021; 8:611351.

PMID: 33912581 PMC: 8072208. DOI: 10.3389/fnut.2021.611351.

Correlation of clinical, radiological and serum analysis of hypovitaminosis D with polycystic ovary syndrome: A systematic review and meta-analysis.

Guraya S, AlHussaini K, Shaqrun F, Alhazmi B, Alkabli R J Taibah Univ Med Sci. 2019; 12(4):277-283.

PMID: 31435252 PMC: 6694940. DOI: 10.1016/j.jtumed.2017.02.005.

Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis.

Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E J Cardiovasc Thorac Res. 2018; 10(2):56-69.

PMID: 30116503 PMC: 6088762. DOI: 10.15171/jcvtr.2018.10.

References

Weinstock-Guttman B, Zivadinov R, Ramanathan M . Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci. 2011; 311(1-2):86-91. DOI: 10.1016/j.jns.2011.07.024. View

Patra S, Nasrat H, Goswami B, Jain A . Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome. Diabetes Metab Syndr. 2012; 6(3):146-9. DOI: 10.1016/j.dsx.2012.09.006. View

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Sahin S, Eroglu M, Selcuk S, Turkgeldi L, Kozali S, Davutoglu S . Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2014; 18(19):2851-6. View

Kilkkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliovaara M . Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol. 2009; 170(8):1032-9. DOI: 10.1093/aje/kwp227. View

Glintborg D, Andersen M, Hagen C, Hermann A . Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin Endocrinol (Oxf). 2005; 62(6):683-91. DOI: 10.1111/j.1365-2265.2005.02280.x. View

Raja-Khan N, Shah J, Stetter C, Lott M, Kunselman A, Dodson W . High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril. 2014; 101(6):1740-6. PMC: 4537163. DOI: 10.1016/j.fertnstert.2014.02.021. View

Fauser B, Tarlatzis B, Rebar R, Legro R, Balen A, Lobo R . Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2011; 97(1):28-38.e25. DOI: 10.1016/j.fertnstert.2011.09.024. View

Kim J, Choi Y, Chae S, Hwang K, Yoon S, Kim M . Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2014; 41(2):80-5. PMC: 4102694. DOI: 10.5653/cerm.2014.41.2.80. View

10.

Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G . The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest. 2009; 33(4):234-8. DOI: 10.1007/BF03345785. View

11.

Alvarez-Blasco F, Botella-Carretero J, San Millan J, Escobar-Morreale H . Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006; 166(19):2081-6. DOI: 10.1001/archinte.166.19.2081. View

12.

Jorde R, Grimnes G . Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011; 50(4):303-12. DOI: 10.1016/j.plipres.2011.05.001. View

13.

Bouillon R, van Schoor N, Gielen E, Boonen S, Mathieu C, Vanderschueren D . Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab. 2013; 98(8):E1283-304. DOI: 10.1210/jc.2013-1195. View

14.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

15.

Tsakova A, Gateva A, Kamenov Z . 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res. 2013; 82(6):399-404. DOI: 10.1024/0300-9831/a000137. View

16.

Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A . Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. Clin Nutr. 2012; 31(4):476-80. DOI: 10.1016/j.clnu.2011.12.010. View

17.

March W, Moore V, Willson K, Phillips D, Norman R, Davies M . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2009; 25(2):544-51. DOI: 10.1093/humrep/dep399. View

18.

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber T . Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009; 161(4):575-82. DOI: 10.1530/EJE-09-0432. View

19.

Li H, Brereton R, Anderson R, Michael Wallace A, Ho C . Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011; 60(10):1475-81. DOI: 10.1016/j.metabol.2011.03.002. View

20.

Ardabili H, Gargari B, Farzadi L . Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. 2012; 32(3):195-201. DOI: 10.1016/j.nutres.2012.02.001. View